Can a drug duo outsmart resistant tumors?

NCT ID NCT05701306

Recruiting now Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial is testing whether two experimental oral drugs, APG-115 and APG-2575, can help people with neuroblastoma or other solid tumors that have returned or not responded to standard treatment. The study will first find the safest dose, then expand to see how well the drugs work, either alone or in combination. Participants must be at least 5 years old for the single-drug part and at least 12 for the combination, and must have no other suitable treatment options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APG-115 (an experimental drug) and APG-2575 (another experimental drug), taken orally, alone or in combination.
What this could lead to: If successful, this could offer a new treatment option for people with hard-to-treat neuroblastoma and other solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial, so the drugs may not work as hoped or may cause significant side effects. The results are preliminary and need further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA SOLID TUMOR

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China
Tongji Hospital, Huazhong University of Science and Technology (HUST)
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.